Shorter weekly regimen of rifapentine-isoniazid effective option for TB prevention in HIV: Study

Written By : Hina Zahid

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2021-08-25 03:30 GMT | Update On 2021-08-25 03:31 GMT

South Africa: People with HIV infection assigned with a shorter weekly course of rifapentine-isoniazid therapy for preventing tuberculosis disease showed a higher treatment completion than those taking a longer daily course, show findings from the WHIP3TB trial. A second treatment round conferred no additional protection from developing tuberculosis disease in high-transmission areas. The study appeared in Annals of Internal Medicine.

Tuberculosis preventive therapy is effective in people with HIV, but its durability is uncertain. Researchers from the Aurum Institute, Houghton, South Africa in the WHIP3TB trial (Weekly High Dose Isoniazid and rifapentine [P] Periodic Prophylaxis for TB trial) hypothesized that, among persons with HIV receiving antiretroviral therapy, treatment completion of weekly rifapentine and isoniazid for 3 months would be superior to 6 months of daily isoniazid, and that annual weekly rifapentine and isoniazid for 3 months would be more effective than a single round.

Also Read: New tuberculosis regimen shortens treatment to four months: Study

The researchers randomly assigned 4,014 persons with HIV who were receiving antiretroviral therapy and did not have active tuberculosis to receive weekly rifapentine–isoniazid for 3 months, given either annually for 2 years or once, or daily isoniazid for 6 months. Participants were screened for tuberculosis symptoms at months 0 to 3 and 12 of each study year and at months 12 and 24. Treatment completion rates, as well as the effectiveness of the different regimens, were compared.

The researchers found that tuberculosis preventive therapy with short-course, weekly rifapentine and isoniazid for 3 months was associated with much higher treatment completion rates compared with standard daily isoniazid for 6 months. In settings with high tuberculosis transmission, a second round of short-course tuberculosis preventive therapy one year later did not provide additional benefit.

Also Read: Health Ministry recommends Tuberculosis screening for COVID positive patients, COVID-19 screening for diagnosed TB patients

DOI: https://www.acpjournals.org/doi/10.7326/M20-7577

Article Source : Annals of Internal Medicine

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Hina Zahid

Hina Zahid Joined Medical Dialogue in 2017 with a passion to work as a Reporter. She coordinates with various national and international journals and association and covers all the stories related to Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in the medical field. Email: editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Shorter weekly regimen of rifapentine-isoniazid effective option for TB prevention in HIV: Study

Similar News

Betel Quid Use Linked to Higher Risk of COPD Deaths, Study Finds

Over Half of Indian Patients With Nasal Symptoms Have Allergic Rhinitis: Study Finds

15 Percent of COPD Exacerbation Patients Develop Arrhythmias, Tripling In-Hospital Death Risk: Meta-Analysis

Mouth Breathing Linked to Sleep-Disordered Breathing in Children, finds study

Minimal-Equipment Pulmonary Rehab Matches Benefits of Full Gym Setup: JAMA

Even healthy children can be severely affected by RSV, reveals research

Breathing device could have profound impact on survival for people with sleep apnoea and type 2 diabetes

Low BMI Raises Risk of TB in IGRA-Positive Contacts, suggests research